Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01335958 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT01335958 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 77 participants.
The verdict
NCT01335958, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
This is a Phase I, multi-center, open-label, dose-escalation study of DMUC5754A administered as a single agent by intravenous (IV) infusion to patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Interventions
- DRUG DMUC5754A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01335958
The ClinicalTrials.gov registry entry for NCT01335958 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DMUC5754A is the first listed.
NCT01335958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01335958 about?
NCT01335958 is a clinical study titled "Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer". This is a Phase I, multi-center, open-label, dose-escalation study of DMUC5754A administered as a single agent by intravenous (IV) infusion to patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
What is the current status of trial NCT01335958?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2011-04. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01335958?
The interventions under investigation include: DMUC5754A (DRUG).
Who is sponsoring clinical trial NCT01335958?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.